Biotechnology Assets Balans Gezondheid
Financiële gezondheid criteriumcontroles 4/6
Biotechnology Assets has a total shareholder equity of €7.2M and total debt of €2.4M, which brings its debt-to-equity ratio to 33.8%. Its total assets and total liabilities are €15.0M and €7.8M respectively.
Belangrijke informatie
33.8%
Verhouding schuld/eigen vermogen
€2.45m
Schuld
| Rente dekkingsratio | n/a |
| Contant | €672.45k |
| Aandelen | €7.23m |
| Totaal verplichtingen | €7.82m |
| Totaal activa | €15.05m |
Analyse van de financiële positie
Kortlopende schulden: BST's short term assets (€2.9M) do not cover its short term liabilities (€3.4M).
Langlopende schulden: BST's short term assets (€2.9M) do not cover its long term liabilities (€4.4M).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: BST's net debt to equity ratio (24.5%) is considered satisfactory.
Schuld verminderen: BST's debt to equity ratio has reduced from 241.5% to 33.8% over the past 5 years.
Balans
Analyse van de cashflow
Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.
Stabiele cash runway: Whilst unprofitable BST has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Voorspelling contante baan: BST is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 43.1% per year.